Overview
- ANMAT‑approved semaglutide 2.4 mg was presented locally for adults with obesity or overweight with comorbidities and for adolescents 12 and older with obesity, administered weekly via a dose‑escalating pen.
- International STEP trials reported an average 17% weight loss versus 2.4% with placebo, with about one in three participants losing at least 20% of initial weight.
- The SELECT outcomes trial found roughly a 20% reduction in major cardiovascular events in people with overweight or obesity and established cardiovascular risk.
- Semaglutide is a GLP‑1 receptor agonist that slows gastric emptying and curbs appetite, with common side effects of nausea and mild gastrointestinal symptoms reported in about 10% of patients.
- Local access remains a concern, with Kairos listing retail prices between ARS 296,000 and 696,000 per presentation, and experts stressing medical supervision, lifestyle support and awareness that stopping therapy can lead to weight regain.